Morgan Stanley sets SpaceX stock price target

Morgan Stanley reiterated its Overweight rating on SpaceX and a $300 price target, which the article says implies a 95% gain from the cited $153.98 share price. Analyst Adam Jonas identified the Distributed Inference Cloud and physical AI as potential growth opportunities; SpaceX revenue is expected to grow 145% in fiscal 2026 despite current losses. The article cites a $2.12 trillion valuation and a $225.64 52-week high; the broader analyst consensus is Moderate Buy.

Analysis

The investable question is not whether distributed inference is strategically interesting, but whether it creates incremental, high-return revenue rather than a story premium. The article supplies no DIC revenue, customer commitments, unit economics, deployment timeline, or capital requirements. Treat the 2026 growth forecast and “Super Intelligence” framing as claims to verify, not evidence that this opportunity is funded or monetizing. At the valuation implied by the article, even a compelling technology narrative may not translate into attractive returns if growth depends on heavy investment or displaces more profitable uses of network capacity.

Near term, analyst endorsement can support sentiment, but the crowded bullish framing limits the value of the note as a fresh catalyst. Over 1–3 months, look for company disclosures that separate DIC from existing businesses and quantify customer demand, capex, and contribution to cash flow. Over 6–18 months, the key competitive test is whether distributed inference offers a cost, latency, or reliability advantage over centralized cloud providers and other edge-computing networks. The contrarian risk is that investors conflate physical-AI adoption with SpaceX capturing the economics. A revised growth outlook, weak cash conversion, or no measurable DIC traction would undermine the thesis; independently verifiable contracts and improving returns on investment would strengthen it.

Key Decisions for Investors

• Do not initiate a position solely on this analyst note; its most differentiated claim is not accompanied by disclosed revenue, customer, or return-on-capital evidence.
• Put SPCX on a catalyst watch: verify DIC-specific bookings or deployments, capex, margins, and cash conversion in company disclosures before paying for the narrative.
• For existing exposure, assess whether position sizing assumes DIC becomes material. Consider reducing or hedging if valuation support depends on that unverified contribution and the company cuts its growth outlook or fails to show commercial traction.
• Revisit a bullish trade only on evidence of paid deployments and improving incremental economics; the thesis is weakened if growth requires rising investment without corresponding cash-flow progress.